Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(450)
•••
Post by davgroon Aug 12, 2022 7:24pm
137 Views
Post# 34893187

The Dumpster is Getting Quite a Reputation as a SH Troll

The Dumpster is Getting Quite a Reputation as a SH TrollHe got called out again on another board for his trolling activities on the XBC board and his total lack of trading knowledge and ridiculous stock activity theories.  Then he moved over to troll BYL.  Nice to see another long established SH member calling him out.

babedinkleman wrote:
Duster340 wrote:
BigHero wrote: This is a bizarre day for Indiva? Somebody know something?


put my stink bid in this morning @14.5, never got a single share somebody knows something
 

LOL poor guy. 
Shame you were bashing over at XBC this morning at 57 cents instead of buying....as it's up 23% over that price on good volume now.  Too funny bro.  Maybe it's best to find a new hobby.  Trolling for stocks at all time lows and being a parasite basher really isn't something to be proud of.  Best of luck.....the $6300 in volume here today and the $2300 yesterday definitely would lead anyone to believe 'someone knows something'   I'm guessing that something is you are currently well underwater in an extremely illiquid stock.  LOL....too funny.


https://stockhouse.com/companies/bullboard?symbol=v.ndva&postid=34892576
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities